Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia
Since the outbreak of novel coronavirus pneumonia (COVID-19), numerous T-cell epitopes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteome have been reported. However, most of the identified CD8+ T-cell epitopes have been restricted primarily by HLA-A allotypes. The epitopes res...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1545510/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849328822441213952 |
|---|---|
| author | Yu Zhao Min Peng Chengtao He Min Li Min Li Xuelian Han Xuelian Han Qiang Fu Yandan Wu Fangping Yue Chunguang Yan Guangyu Zhao Guangyu Zhao Chuanlai Shen |
| author_facet | Yu Zhao Min Peng Chengtao He Min Li Min Li Xuelian Han Xuelian Han Qiang Fu Yandan Wu Fangping Yue Chunguang Yan Guangyu Zhao Guangyu Zhao Chuanlai Shen |
| author_sort | Yu Zhao |
| collection | DOAJ |
| description | Since the outbreak of novel coronavirus pneumonia (COVID-19), numerous T-cell epitopes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteome have been reported. However, most of the identified CD8+ T-cell epitopes have been restricted primarily by HLA-A allotypes. The epitopes restricted by HLA-B and HLA-C allotypes are limited. This study focuses on the screening of T-cell epitopes restricted by 13 prevalent HLA-B and 13 prevalent HLA-C allotypes, which cover over 70% and 90% of the Chinese and Northeast Asian populations, respectively. Totally, 67 HLA-B restricted and 53 HLA-C restricted epitopes were validated as immunogenic epitopes with a herd predominance rate by peptide-PBMCs ex vivo coculture experiments using the PBMCs from convalescent Chinese cohort. In addition, 26 transfected cell lines expressing indicated HLA-B or HLA-C allotype were established, and used in the competitive peptide binding assays to define the affinities and cross-restriction of each validated epitope binding to HLA-B or HLA-C allotypes. These data will facilitate the design of T-cell-directed vaccines and SARS-CoV-2-specific T-cell detection tools tailored to the Northeast Asian population. The herd test of functionally validated T-cell epitopes, and the competitive peptide binding assay onto cell line array expressing prevalent HLA allotypes may serve as an additional criterion for selecting T-cell epitopes used in vaccine. |
| format | Article |
| id | doaj-art-f14bffff63f14fa8b89dcecf0d0634f5 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-f14bffff63f14fa8b89dcecf0d0634f52025-08-20T03:47:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15455101545510Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast AsiaYu Zhao0Min Peng1Chengtao He2Min Li3Min Li4Xuelian Han5Xuelian Han6Qiang Fu7Yandan Wu8Fangping Yue9Chunguang Yan10Guangyu Zhao11Guangyu Zhao12Chuanlai Shen13Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, ChinaBlood Group Reference Laboratory, Nanjing Red Cross Blood Center, Nanjing, ChinaState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, ChinaLaboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, ChinaState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, ChinaLaboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, ChinaBlood Group Reference Laboratory, Nanjing Red Cross Blood Center, Nanjing, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, ChinaState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, ChinaLaboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, ChinaSince the outbreak of novel coronavirus pneumonia (COVID-19), numerous T-cell epitopes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteome have been reported. However, most of the identified CD8+ T-cell epitopes have been restricted primarily by HLA-A allotypes. The epitopes restricted by HLA-B and HLA-C allotypes are limited. This study focuses on the screening of T-cell epitopes restricted by 13 prevalent HLA-B and 13 prevalent HLA-C allotypes, which cover over 70% and 90% of the Chinese and Northeast Asian populations, respectively. Totally, 67 HLA-B restricted and 53 HLA-C restricted epitopes were validated as immunogenic epitopes with a herd predominance rate by peptide-PBMCs ex vivo coculture experiments using the PBMCs from convalescent Chinese cohort. In addition, 26 transfected cell lines expressing indicated HLA-B or HLA-C allotype were established, and used in the competitive peptide binding assays to define the affinities and cross-restriction of each validated epitope binding to HLA-B or HLA-C allotypes. These data will facilitate the design of T-cell-directed vaccines and SARS-CoV-2-specific T-cell detection tools tailored to the Northeast Asian population. The herd test of functionally validated T-cell epitopes, and the competitive peptide binding assay onto cell line array expressing prevalent HLA allotypes may serve as an additional criterion for selecting T-cell epitopes used in vaccine.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1545510/fullSARS-CoV-2HLA-B allotypeHLA-C allotypeT-cell epitopevaccine |
| spellingShingle | Yu Zhao Min Peng Chengtao He Min Li Min Li Xuelian Han Xuelian Han Qiang Fu Yandan Wu Fangping Yue Chunguang Yan Guangyu Zhao Guangyu Zhao Chuanlai Shen Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia Frontiers in Immunology SARS-CoV-2 HLA-B allotype HLA-C allotype T-cell epitope vaccine |
| title | Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia |
| title_full | Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia |
| title_fullStr | Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia |
| title_full_unstemmed | Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia |
| title_short | Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia |
| title_sort | predominant t cell epitopes of sars cov 2 restricted by multiple prevalent hla b and hla c allotypes in northeast asia |
| topic | SARS-CoV-2 HLA-B allotype HLA-C allotype T-cell epitope vaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1545510/full |
| work_keys_str_mv | AT yuzhao predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT minpeng predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT chengtaohe predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT minli predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT minli predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT xuelianhan predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT xuelianhan predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT qiangfu predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT yandanwu predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT fangpingyue predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT chunguangyan predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT guangyuzhao predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT guangyuzhao predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia AT chuanlaishen predominanttcellepitopesofsarscov2restrictedbymultipleprevalenthlabandhlacallotypesinnortheastasia |